In Brief
Ehmsen et al. identify cholesterol biosynthesis as essential for breast cancer stem cell propagation. Increased expression of multiple cholesterol biosynthesis proteins is observed in mammospheres, and the expression levels of these proteins correlate with the outcome of basal-like breast cancer patients. Inhibition of the cholesterol biosynthesis pathway reduces mammosphere formation.
SUMMARY
Tumor eradication may be greatly improved by targeting cancer stem cells (CSCs), as they exhibit resistance to conventional therapy. To gain insight into the unique biology of CSCs, we developed patient-derived xenograft tumors (PDXs) from ER À breast cancers from which we isolated mammospheres that are enriched for CSCs. Comparative global proteomic analysis was performed on patient tumor tissues and corresponding PDXs and mammospheres. Mammospheres exhibited increased expression of proteins associated with de novo cholesterol synthesis. The clinical relevance of increased cholesterol biosynthesis was verified in a large breast cancer cohort showing correlation with shorter relapse-free survival. RNAi and chemical inhibition of the cholesterol biosynthesis pathway reduced mammosphere formation, which could be rescued by a downstream metabolite. Our findings identify the cholesterol biosynthesis pathway as central for CSC propagation and a potential therapeutic target, as well as providing a mechanistic explanation for the therapeutic benefit of statins in breast cancer.
INTRODUCTION
Cancer stem cells (CSCs) are described as exhibiting selfrenewal and differentiation capabilities (Visvader and Lindeman, 2008) and cancer therapy resistance (Saito et al., 2010) , factors believed to be responsible for poor clinical outcome in many cancer types . Breast CSCs have previously been described to express CD44 + , CD24 À (Al-Hajj et al., 2003) , or ALDH + (Ginestier et al., 2007) , markers conserved in primary tumors, circulating tumor cells, and distant metastases, and are thus useful for cancer detection and prognostic evaluation (Li et al., 2017) . However, other markers, such as CD49f hi Epcam À/lo (Stingl et al., 2001; Visvader, 2009 ), have also been described as CSC markers. One method to enrich for CSCs is based on their expression of these markers using fluorescence-activated cell sorting (FACS) analysis (Colacino et al., 2018) . However, focusing alone on specific markers analyzed by FACS may restrict the identified breast CSCs too much, and thus other methods, such as anchorage-independent growth of cancer cells to generate 3D culture of spheres, may be beneficial for CSC enrichment (Christensen et al., 2017) ; it has been shown to enrich for cells with CSC-like properties (Shaw et al., 2012) . During suspension growth, most epithelial cells are killed by anoikis and the resulting mammospheres are formed by the clonal expansion of a single cell instead of the self-aggregation of existing cells (Shaw et al., 2012) . Pre-clinical models serve to test hypotheses and are central to cancer research (Whittle et al., 2015) . The model of choice has often been long-established cancer cell lines; however, molecular profiling of the NCI-60 panel of well-established cancer cell lines compared to primary human cancer tissues revealed that cell lines cluster with cell lines instead of their tissue of origin (Gillet et al., 2011) . In addition, extensive clonal selection during passaging has resulted in loss of heterogeneity (Ellis and Fidler, 2010) . To understand human tumor biology with multiple subclones (Shah et al., 2009) , including CSCs, researchers are turning toward patient-derived xenograft (PDX) (Byrne et al., 2017 ) models comprising immune-deficient mice engrafted with patient tumor material (Siolas and Hannon, 2013) . PDX models of breast cancer have been shown to reflect patient tumors with regard to histopathology and gene expression (Zhang et al., 2013; Byrne et al., 2017) and to retain intra-tumor heterogeneity during several passages (Bruna et al., 2016) , as well as mutations of the primary tumor of origin (Bruna et al., 2016; Ding et al., 2010; Jung et al., 2018) . However, some studies have shown that therapeutic intervention or the process of adapting to growth in a new organ increases the mutation prevalence of minor clones in PDXs during passaging (Ding et al., 2012; Li et al., 2013) .
In this study, we aimed to isolate clinically relevant CSCs from breast cancer patients and identify biological pathways important for CSC function that may serve as targets for future treatments and ultimately reduce the risk of recurrence. Thus, we generated PDX tumors from the primary tissue of human estrogen receptor-negative (ER À ) breast cancers and also generated mammospheres by growing single-cell suspensions from excised PDX tumors under adherent-free conditions, using mass spectrometry-based proteomics to identify significantly altered proteins in the generated mammospheres and PDX tumors. GO enrichment analysis of proteins elevated in mammosphere samples compared to PDX tumors identified cholesterol biosynthesis as being the most significantly activated process in mammospheres. High expression of cholesterol synthesis genes was found to be associated with short relapse-free survival in basal-like ER À breast cancer patients. In addition, inhibition of the cholesterol biosynthesis pathway in mammospheres derived from PDX tumors and from triple-negative breast cancer (TNBC) cell lines resulted in significantly reduced mammosphere formation and growth, suggesting that the cholesterol biosynthesis pathway is central for CSC growth and may represent a provocative potential target for CSC elimination.
RESULTS

Patient Characteristics
Fresh tumor tissue samples from 6 ER À breast cancer patients, none of whom had received neoadjuvant treatment, were directly snap frozen and proteomes from 4 were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/ MS) (Pri02, Pri08, Pri12, and Pri18), while a piece of the tissue sample was transplanted into the mammary fat pad of female NOG mice to generate PDX tumors for subsequent LC-MS/MS analyses (PDX03, PDX05, PDX08, PDX12, and PDX18) (Figure 1 ). In addition, 2 PDXs were regrafted (PDX05p2 and PDX08p2) and analyzed by LC-MS/MS. Finally, single cells from 4 of the PDXs were isolated and seeded in low-attachment plates to obtain mammospheres (Mam03, Mam08p2, Mam12, and Mam18), and these were also analyzed by LC-MS/MS. The clinical characteristics of the ER À breast cancer patients are provided in Table S1 .
Proteomic Comparison of PDX Tumors and Corresponding Patient Tumor Tissue
Differences in proteome profiles between the PDXs (including the regrafted PDXs) and the patient breast cancer tissue, and between the PDXs and the derived mammospheres, were compared. Analysis of the patient tumor samples and corresponding PDX tumors identified 1,692 human proteins by at least 2 peptide spectral matches (PSMs) in 50% of the samples in each group. Unsupervised cluster analysis of the patient tumor samples and PDX tumors using all of the 1,692 identified proteins revealed that the PDX samples generally clustered together, as did the patient tumor samples, although the Pri12-PDX12 pair exhibited great similarity (Figure 2A ). This indicates that despite the similarities between the original patient tumor and the derived PDX, alterations in protein levels are present, including proteins in the original patient tumor that are lost in the PDX, such as immune-, blood-, and ECM-related proteins and cellto-cell adhesion proteins. Of the 1,692 identified human proteins, 341 exhibited significantly altered expression levels (R2-fold, p < 0.05) between patient tumor tissue and the PDXs (Table  S2) . Supervised cluster analysis focusing on the 341 differentially expressed proteins revealed that the 2 regrafted PDX tumors clustered closely together with the PDX from which they were derived: PDX08p2 from PDX08 and PDX05p2 from PDX05 ( Figure 2B ). This finding was supported by scatterplot analysis of the total regulated proteins for the 2 pairs, exhibiting R 2 values > 0.85 ( Figure S1 ). Similar scatterplot results were obtained for the significantly regulated proteins for the 2 pairs (data not shown), indicating that the proteomic composition of PDXs was quite stable upon passaging.
Network and GO Analysis of Significantly Altered Proteins between PDX Tumors and Corresponding Patient Tumor Samples To elucidate the underlying biological differences between the patient tumor samples and PDX tumors, the 341 proteins exhibiting significant altered expression were subjected to Ingenuity Pathway Analysis (IPA). The top network was found to be associated with cellular growth, development, and movement ( Figures 3A and 3B) . All of the significant networks are listed in Figure 3B .
Of the 341 proteins exhibiting altered expression between the patient tumor samples and PDX tumors, 80 were elevated and 261 were decreased in the PDX samples. Those proteins found to be decreased in PDX tissue were dominated by immune-, blood-, and extracellular matrix (ECM)-related proteins (Table S3 ). In addition, among the tumor cell-derived proteins identified to be decreased in the PDX versus patient tumor samples, several were related to lipoprotein formations, including chylomicron (n = 7, q value = 6.3 3 10 À9 ), as determined by GO analysis. The most downregulated proteins associated with lipoprotein formations included the apolipoproteins APOE (94-fold decreased), APOC1 (13-fold decreased), APOA4 (37-fold decreased), APOC3 (19-fold decreased), APOA1 (595-fold decreased), APOA2 (152-fold decreased), APOB (85-fold decreased), and APOH (119-fold decreased). Proteins associated with cholesterol biosynthesis did not exhibit altered levels. Analysis of the proteins elevated in PDX versus patient tumor samples revealed desmosome, a cell structure specialized for cell-to-cell adhesion, as one of the most significantly enriched components (p = 9.5 3 10 À4 ). The elevated desmosome proteins included plakophilin-3 (PKP3; 25-fold elevated), desmoglein-3 (DSG3, 17.4-fold elevated), and junction plakoglobin (JUP, 3.6-fold elevated). Also elevated (2.5-fold) was b-catenin (CTNNB1), which is involved in adherens junctions of cell-to-cell adhesion, Figure S2A , and the quantification of the IHC stainings, as determined using H-scores, is provided in Table S4 .
but also acts as the key switch in the canonical Wnt signaling pathway that has been shown to modify the in vivo tumorigenicity of TNBC cell lines (Xu et al., 2015) . The increased b-catenin and PKP3 expression in PDX tumors versus patient tumor samples was verified by immunohistochemistry ( Figures  3C and S2A ; Table S4 .
Proteomic Comparison of PDX Tumors and Derived Mammospheres
To gain insights into the biological characteristics of CSCs, we dissociated the PDX tumors using a gentleMACS dissociator and propagated the resulting single-cell suspensions at low cell concentrations in de-differentiating medium using ultra-low attachment plates. After 9 days of incubation, the resulting mammospheres were separated from the remaining cells of the culture for comparative mass spectrometrybased proteomic analysis. Comparison of the proteome profile of the mammospheres and PDX groups identified 1,399 human proteins in common, 493 of which were significantly altered in abundance (±2-fold, p < 0.05) as determined by EdgeR analysis. Of the altered proteins, 105 were elevated and 380 decreased in mammospheres compared to PDXs (Table S5) . ALDH1A1 has previously been described as a breast cancer CSC marker (Ginestier et al., 2007) , and we found this protein to be significantly (p = 0.04) upregulated in mammosphere samples compared to PDX samples. Hierarchical unsupervised cluster analysis of the 1,399 commonly identified proteins revealed that the mammosphere samples generally clustered together, and while the same was true for the Pri12-PDX12 samples, the Mam12-PDX12 pair exhibited great similarity (Figure 4A) . Subsequently, supervised cluster analysis of the 493 significantly altered proteins (R2-fold, p < 0.05) between the mammosphere samples and PDXs showed that the mammosphere samples clustered together, as did the PDX samples ( Figure 4B ). Cholesterol BiosynthesisAssociated Proteins Are Elevated in Mammospheres Compared to PDX Tumors Upstream analysis of the altered proteins between the mammosphere samples and the PDX samples (n = 493, >2-fold) using IPA revealed, with a high confidence score (activation Z score = 2.12; p = 2.69 3 10 À3 ), the heat shock factor 1 (HSF1) to be activated ( Figure S2B ). In normal cells, HSF1 acts as a transcription factor and regulates the heat shock response pathway, whereas in cancer cells, it probably has other functions and has recently been described as playing a role in the growth of breast CSCs and metastasis (Carpenter et al., 2017) . Among the 105 elevated proteins in the mammosphere versus PDX samples, GO enrichment analysis identified endoplasmic reticulum (ER) membrane-associated proteins (n = 23) (Table S6) to be significantly enriched with a Fisher's test q value of 3.8 3 10 À9 . In addition, a highly significant enrichment for GO terms associated with cholesterol biosynthesis was identified (n = 8, q = 1.1 3 10 À7 ) (Table S6 ). The cholesterol biosynthetic process dataset in EnrichNet consists of only 34 genes in total, and the high abundance of elevated proteins associated with this pathway in the mammosphere samples suggests an important function of cholesterol biosynthesis in mammosphere formation and function. Critically, when examining the 380 proteins decreased in abundance in mammospheres compared to PDX tumors, only 1 protein was associated with the cholesterol biosynthetic process (cellular nucleic acid-binding protein [CNBP] ), indicating a general activation of cholesterol biosynthesis in mammosphere samples. The high-cholesterol synthesis profile of the mammospheres was likewise identified by the IPA analysis of all of the proteins elevated in mammospheres versus PDX samples, with the 4 significant canonical pathways being cholesterol synthesis related ( Figure 5A ). Furthermore, pathway analysis of all of the altered proteins between the mammospheres versus PDX samples using IPA revealed p53 to be an upstream regulator of several of the cholesterol biosynthesis proteins (Figure S2C ). Of the 8 elevated cholesterol synthesis proteins, 7 are directly involved in the enzymatic catalytic steps, including HMGCS1, FDPS, FDFT1, LSS, NSDHL, EBP, and DHCR7 (Figure 5B ), whereas CYB5R3 functions as a reductase enzyme in the ER membrane. Evaluation of the expression levels of the cholesterol synthesis-associated proteins in the individual mammospheres and PDX samples showed that the 8 proteins were generally elevated in the mammosphere samples and generally decreased in the PDX tumors ( Figure 5C ). To further confirm this difference in expression, MB231 cells grown as 2D cell culture, as mammospheres, or as xenograft tumors in vivo were stained for FDFT1 and CYB5R3. There was no or very low expression of FDFT1 and CYB5R3 in MB231 cells grown in 2D cell culture, higher expression in xenograft tumors, and the highest expression in mammospheres ( Figure 5D ; Table S7 ). FDFT1 expression in xenograft tumors varied from very low to medium expression within the tumor. The result indicates that the difference in expression between xenograft tumors and mammosphere samples is not due to differences between in vivo and in vitro conditions.
High Expression of Cholesterol Biosynthesis Genes Is Associated with Worse Prognosis in Basal-like Breast Cancer Patients
To evaluate the clinical relevance of the 8 elevated cholesterol biosynthesis proteins, we evaluated their prognostic significance in a cohort of 615 basal-like breast cancer patients using the gene expression survival analysis tool KM Plotter. All cholesterol synthesis-associated proteins, except for DHCR7 or LSS, showed a significant correlation between high gene expression and shorter relapse-free survival in the basal-like breast cancer cohort ( Figure 6 ), while no correlation with overall survival was observed (data not shown). When combining the gene expression data of the 5 cholesterol biosynthesis-associated proteins that showed a significant correlation between high expression and shorter relapse-free survival (EBP, HMGCS1, FDPS, FDFT, and NSDHL) in a multigene classifier, no additional reduction in relapse-free survival in basal-like breast cancer patients was observed using the multigene classifier option in KM Plotter ( Figure 6H ). Similarly, no benefit was observed when combining smaller numbers of the 5 genes. In addition, we found no evidence for co-regulation of the 5 genes when evaluating the square of the correlation coefficient (R 2 ) and the variation inflation factors (VIFs) in a multiple regression analysis of gene expression in a cohort of 77 ER À breast cancer patients (Wang et al., 2005 ; Figure S2D ).
Inhibition of the Cholesterol Biosynthesis Pathway Decreases Mammosphere Formation
To evaluate the importance of the cholesterol pathway in CSCs, we examined the effect of simvastatin treatment on mammosphere respectively. Quantification of the IHC stainings, as determined using H-scores, is provided in Table S7. formation. Simvastatin inhibits the rate-limiting enzyme in the cholesterol biosynthesis pathway, 3-hydroxy-3-methyl-glutarylcoenzyme A (HMG-CoA) reductase. Single-cell suspensions of 3 excised PDX tumors (PDX08p2 and 2 additional ER À PDXs, , and NSDHL in a multigene classifier (H). Plots were generated using the online survival analysis tool KM Plotter using 10 years of follow-up time, right censuring, and optimal cutoff values.
PDX20 and PDX21) were isolated and seeded in a mammosphere assay and cultured in the presence of 0.02 or 0.2 mM simvastatin or 1% DMSO. The optimal simvastatin concentration was determined beforehand in a toxicity assay ( Figure S3A ). Mammosphere forming efficiency (MFE) was determined based on the incidence rate ratio (IRR) and Poisson regression and expressed as a percentage. The results showed that increasing concentrations of simvastatin significantly reduced mammosphere formation for all PDX tumors ( Figure 7A ). In addition, we examined whether the MFE of TNBC cell lines was altered after gene knockdown of 2 of the elevated cholesterol biosynthesis proteins, FDFT1 and CYB5R3. Two different specific small interfering RNAs (siRNAs) and a scrambled control siRNA were used for the knockdown experiment of each gene, and knockdown was examined in 2 TNBC cell lines, MB231 and MB468, resulting in an up to 90% reduction in gene expression levels (Figures S3B and S3C) . A significant reduction in MFEs was observed in both TNBC cell lines using both specific siRNAs compared to the scrambled control for both genes (Figure 7B ), whereas the siRNAs did not affect 2D cell growth ( Figures S3D and S3E ). In addition, a rescue experiment was performed wherein mevalonolactone, which exists in equilibrium with mevalonic acid in the cholesterol pathway, was added to MB231 siRNA knockdown cells and to scrambled control cells. Complete rescue with MFE at the same level as the untreated scrambled control cells was observed ( Figure 7B ). Simvastatin significantly inhibited proliferation under nonadherent conditions of MB231 cells and reduced mammosphere formation to 60% (p = 0.07) when treated with 10 mM simvastatin ( Figures S3F and S3G ). MB231 has previously been shown to be sensitive to 10 mM simvastatin, while MB468 was reportedly less sensitive (Jung et al., 2016) . We consistently observed MB468 cells to be insensitive to simvastatin in regard to mammosphere formation and proliferation under non-adherent conditions ( Figures S3F  and S3G ). Oil red O was used to assess the collective triglyceride, lipid, and cholesterol content in PDX samples versus corresponding mammosphere samples. We further stained with an anti-PLIN2 antibody. PLIN2 participates in fatty acid uptake and is a marker of lipid droplet accumulation (Zhang et al., 2018) . Increased staining for both markers was observed in mammospheres versus PDX.
DISCUSSION
Recently, therapeutics that specifically target CSCs have been considered as an attractive addition to standard treatments to In addition, in a rescue experiment, FDFT1 and CYB5R3 knockdown MB231 cells were treated with mevalonolactone, the lactone form of mevalonic acid, and the effect on MFE (%) was evaluated. Cells were seeded with an average of 2,000 cells per well and grown for 6 days before MFE analysis. The effect of siRNA knockdown on the MFE was evaluated based on the IRR using Poisson regression, with the significance level p < 0.05. The experiment was performed in biological triplicate. (C) Oil red O (ORO) and anti-PLIN2 antibody staining of PDX tissue and corresponding mammospheres. Scale bar, 100 mm.
reduce the risk of recurrence, as most contemporary treatment regimens predominantly target the bulk tumor and not CSCs. It is becoming clear that CSCs are not easily distinguished from more differentiated cell types by a single or a few cell surface proteins. Searching for broader biological pathways that are important for CSC function may offer an additional approach in the search for essential targets. So far, critical pathways for CSC function in breast cancer include Notch signaling (Grudzien et al., 2010) , Hedgehog signaling (Liu et al., 2006) , Hippo signaling (Cordenonsi et al., 2011) , and b-catenin and nuclear factor kB (NF-kB) signaling (Christensen et al., 2017) .
Here, we identified a highly active metabolic program associated with cholesterol biosynthesis as an additional pathway central for CSCs, a finding established by proteomic profiling comparing paired samples of patient tumor tissue, derived PDXs, and mammospheres, known to be enriched for CSCs. In general, cholesterol plays an important role in the structure of membranes and the function of membrane-localized proteins, as well as in cell proliferation and cell survival (Goldstein and Brown, 1990; Liu et al., 2016) . In breast cancer, total cholesterol is a poor prognostic factor (Boyd and McGuire, 1990; Ferraroni et al., 1993; Kitahara et al., 2011) , and statin use has been associated with increased recurrence-free survival (Ahern et al., 2011; Nielsen et al., 2012; Borgquist et al., 2017) . In relation to CSCs, transcriptional activation of the cholesterol biosynthesis pathway has recently been demonstrated (Liu et al., 2016) to play an important function in neurospheres, the neurological equivalent to mammospheres. Furthermore, a study on radiation resistance in pancreatic cancer showed that cholesterol biosynthesis was consistently upregulated among radiation-resistant pathways (Souchek et al., 2014) . In our study, we identified nearly the same altered proteins as in the 2 above-mentioned studies at the transcriptomic level, including LSS, FDPS, FDFT1, HMGCS1, NSDHL, EBP, and DHCR7, suggesting that this part of the cholesterol biosynthesis pathway plays an important role, not only in breast cancer CSC but also in CSCs of other cancer origins. In addition, Liu and colleagues found that inhibition of the cholesterol biosynthesis pathway resulted in a marked decrease in the tumorigenicity of mouse neuroblastoma neurospheres and human neuroblastoma cell lines (Liu et al., 2016; Souchek et al., 2014) . Supporting these findings, we show that siRNA-mediated silencing of FDFT1 in 2 TNBC cell lines, MB231 and MB468, reduced mammosphere formation, and that the effect could be rescued by adding a downstream metabolite, further substantiating the cholesterol biosynthesis pathway as important for the growth of CSCs.
Reprogramming and hijacking of existing metabolic pathways to sustain energetic and biosynthetic needs is a well-established characteristic of cancer cells, but it seems that CSCs are even more efficient in this process compared to more differentiated cancer cells. In a recent large siRNA screening study in which $4,800 druggable genes were analyzed in a 3D culture setting, cholesterol biosynthesis and synthesis of unsaturated fatty acids pathways were found to be the only selective CSC druggable targets (Song et al., 2017) . Inhibition of the mevalonate pathway with farnesyltransferase inhibitors (FTIs) or HMG-CoA reductase inhibitors (statins) has shown promise in preclinical breast cancer studies. FTIs have been shown to improve breast cancer prognosis in a phase II clinical trial (Johnston et al., 2003) , especially for TNBC (Brewer et al., 2013) , and statins have been shown in various breast cancer cell lines to increase apoptosis and decrease the metastatic dissemination of tumors (Van Wyhe et al., 2017) . Not all breast cancer cell lines are sensitive to statins, and a very recent study suggests that de novo cholesterol biosynthesis is not required for statin-resistant cell proliferation since these cells increase the exogenous uptake of cholesterol and lipids by increasing the transcription of, for example, 3-hydroxy-3-methylglutarylCoA reductase (HMGCR) (Lettiero et al., 2018) . Simvastatin is being evaluated in a phase II clinical trial for metastatic HER2 + breast cancer (Rimawi, 2019) . In our study, we showed that simvastatin inhibits mammosphere formation and growth of CSCs from PDX tumors derived from TNBCs, further supporting the suggestion that inhibition of the cholesterol biosynthesis pathway may contribute to TNBC treatment. Loss of prenylation and farnesylation upon simvastatin treatment seems not to be the major reason for decreased mammosphere formation, since knockdown of downstream enzymes resulted in the same phenotype.
Recently, it has been shown that the cholesterol metabolite 27-hydroxycholesterol may actively signal through the ER (Nelson et al., 2013) , providing a potential mechanism in some breast CSCs, although the major focus of this study was on TNBCs that do not express the ER. Furthermore, 27-hydroxycholesterol has been shown to act on neutrophils and gd-T cells residing at distal metastatic sites, thereby promoting an immunosuppressive environment (Baek et al., 2017) .
The heat shock factor HSF1 and p53 were predicted by IPA to be upstream regulators of the altered proteins in our dataset, including those of the cholesterol biosynthesis pathway. The Akt-HSF1 pathway has previously been associated with the shortened survival of breast cancer patients, and the combined targeting of Akt and HSF1 reduced tumor growth, delayed metastasis, and prolonged survival in an orthotopic xenograft mouse model (Carpenter et al., 2017) . The study also showed that siRNA-mediated silencing of HSF1 in several breast cancer cell lines, including MDA-MB-231, reduced the ability of cells to form and grow mammospheres (Carpenter et al., 2017) . A recent study detailed the link between p53 and cholesterol biosynthesis (Moon et al., 2019) , showing that p53 suppresses the mevalonate pathway by blocking the activation of SREBP-2, the master transcriptional regulator of this pathway. Furthermore, the study also showed that p53 null liver tumorigenesis in mice depends on activation of the mevalonate pathway.
In this study, we also examined the similarities and differences between the proteome profiles of patient breast tumor samples and corresponding PDX tumors. Immunohistochemistry and gene expression studies previously showed significant similarities between PDX tumors and the corresponding patient tumor tissues and supported PDX tumor models as more clinically relevant than xenograft models based on tumor cell lines (Tentler et al., 2012) . In our datasets, we also observed marked similarities in the proteome profiles. When evaluating differentially expressed proteins between the patient-PDX tumor pairs, we found that the less-represented proteins in the PDX versus patient tumor samples were immune related or ECM related or involved in the stromal compartment and lipoprotein formation. The loss of these proteins is probably due to the replacement of the human stroma by murine elements when the human tumors were propagated in immunodeficient mice. Genes involved in the same tissues have previously been shown to interfere with the alignment of patient and PDX tumors (Sivanand et al., 2012) .
Among the elevated proteins in the PDX versus patient tumor samples, we identified proteins associated with angiogenesis and cell-to-cell adhesion, including desmosome proteins (e.g., PKP3) and b-catenin. These results suggest that the intercellular junctions that provide strong adhesion between cells become more abundant in PDXs, allowing the tissue to withstand mechanical forces (Nusse and Clevers, 2017) . The reason for this upregulation is not clear and needs further investigation.
In conclusion, our study reveals that increased activation of the cholesterol biosynthesis pathways is a key feature of CSCs from TNBC, as suggested by both functional studies and correlation with clinical outcome data. Our study further reveals that blocking the cholesterol biosynthesis pathway in CSCs reduces mammosphere formation and growth, suggesting the 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Participants
Female adult ER-breast cancer patients (n = 9) who underwent surgery at Odense University Hospital, Denmark were included in the study (patients 02, 03, 05, 08, 12 and 18). All clinical samples were coded to maintain patient confidentiality and the study was approved by the Ethics Committee of the Region of Southern Denmark (approval no S-2008-0115) and the Danish Data Protection Agency (approval no. 2008-580035 (14/10607)).
PDX
Tissue pieces from female adult ER-breast cancer patients (n = 8) who underwent surgery at Odense University Hospital, Denmark were transplanted into the mammary fat pad of female CIEA NOG-F mice (Taconic).
Mice
For in vivo studies, eight week-old CIEA NOG-F (NOD.Cg-Prkdc scid Il2rg tm1Sug /JicTac), treatment naive, female mice were used. The animal were housed under specific free pathogen conditions at the central animal facility (Biomedical Laboratory, University of Southern Denmark) at a temperature of 20 -22 C, a relative humidity of 45 -65% and day-night cycle of 12 h. The animals were fed on a standard chow and had ad libitum access to drinking water from bottles. The genotype of the animals was associated with multiple immunodeficiency as described by Ito et al. (2002) . The experiments were approved by the Danish Animal Experiments Inspectorate. The mice were euthanized by cervical dislocation at the end of the experiment or when endpoints were reached, i.e., tumor growth for 6 months or a tumor size of 12 mm.
Cell lines
The human TNBC cell lines, derived from metastatic sites, MDA-MB-468 (MB468) and MDA-MB-231 (MB231) were obtained from ATCC and maintained in DMEM (Sigma) supplemented with 10% fetal bovine serum (FBS, Sigma) and 1% p/s. Cells were grown in 5% CO 2 at 37 C. When cells were approximately 70%-80% confluent, they were harvested for experiments or split at ratios between 1:2 and 1:6. For normal maintenance, cells were incubated with trypsin (Promega) for 5 min at 37 C, but for harvest for experiments, cells were incubated with Accutase (EMD Millipore) 10-15 min at 37 C. For mammosphere assays, cell lines were grown in DMEM medium supplemented with 1% p/s, insulin (5 mg/mL, Sigma), bovine serum albumin (BSA 0.4% in PBS, Sigma), bFGF (20 ng/mL, VWR) and EGF (10 ng/mL, Sigma). The identity of the cell lines according to ATCC was verified using DNA fingerprinting by short tandem repeat (STR) analysis (Cell IDTM system, Promega). Cell lines were frequently tested for mycoplasma (MycoAlertâ, Mycoplasma detection kit, Lonza). For immunocytochemistry, the MB231 cell line was harvested, resuspended in complete growth media and centrifuged at 300 x g for 5 min at RT. Cells were washed twice in HEPES buffer (10 mM HEPES, 140 mM NaCl, 10 mM KCl, 5 mM D-Glucose, 2 mM EDTA, 2 mM CaCl 2 -2hydrat) with centrifugation at 300 x g for 5 min in between. Cells were fixed in 4% formaldehyde for 48 h at RT and subsequently paraffin-embedded. For in vivo studies, MB231 cells (10 6 cells per mouse) were harvested using accutase and resuspended in 1:1 mixture of Engelbreth-Holm-Swarm sarcoma (Sigma) and culture media. The cells were orthotropically transplanted into surgically-exposed mammary fat pads of anesthetized 8 week-old NOG female mice. By endpoint, the mice were euthanized by cervical dislocation, the tumors were removed and fixed in formalin for 48 h and subsequently paraffin-embedded.
METHOD DETAILS
Tissue preparation and generation of PDX Fresh tumor tissues from female ER-negative, breast cancer patients who underwent surgery at Odense University Hospital, Denmark, were isolated, and one part of the sample was snap-frozen in 50 mM Na 2 CO 3 buffer with protease inhibitors (Roche) in liquid nitrogen and stored at À80
C until mass spectrometric analysis. Another sample from the same tumor was transplanted into the mammary fat pad of a female NOG mouse (Taconic) to generate PDXs. Briefly, a small incision was made in the skin to expose the mammary fat pad of the anaesthetized mouse. Extracellular matrix (ECM, Sigma-Aldrich) was injected into the mammary fat pad at the site of transplantation and a small incision was made and a 2 mm tumor cube was inserted (DeRose et al., 2013) . The incision in the mammary fat pad was sealed using 6.0 sutures and the skin was closed using Reflex 7 mm wound clips (Agnthos, Sweden).
Generation and harvest of PDX mammospheres PDX tumors were surgically excised when tumors reached 12 mm as assessed by caliber measurement, and half of the sample was snap-frozen in liquid nitrogen in 50 mM Na 2 CO 3 with protease inhibitors (Roche) and stored at À80
C for mass spectrometry analysis. The other half was used to obtain a single cell suspension by cutting it into small cubes (2-4 mm) and placing it in a gentleMACS C-tube (Miltenyi, Germany) containing tumor dissociation buffer (4.7 mL Dulbecco's Modified Eagle's medium (DMEM), 200 mL Enzyme H, 100 mL Enzyme R and 25 mL of Enzyme A (130-095-929, Miltenyi, Germany)) and processed using the program h_TDK_3 at 37 C on the gentleMACS Octo Dissociator. The dissociated PDX cells were applied to a MACS SmartStrainer (70 mm) placed on a 50 mL Falcon tube. The SmartStrainer was washed with 20 mL DMEM and the combined suspension ($25 mL) was washed sequentially over the strainer three times. The resulting single cell suspension was centrifuged at 300 x g for 7 min. The supernatant was aspirated completely and the cell pellet was carefully redissolved in 1 mL mammosphere medium (DMEM:F12 supplemented with B27 minus vitamin A (ThermoFisher Scientific), hydrocortisone (5 mg/mL, Lonza), insulin 5 mg/mL (Sigma), EGF 10 ng/mL (Peprotech) and 5% penicillin/streptomycin (p/s, Sigma)). Cells were counted on a hemocytometer and seeded in 6-well ultralow binding plates (Sigma) with 5000 cells/cm 2 in 5 mL mammosphere medium. Cells were incubated for 9 days at 37 C at 5% CO 2 , after which large mammospheres (> 50 mm) were harvested under a microscope using a P10 pipette. The mammospheres were transferred to a 1.5 mL Eppendorf-tube containing 500 mL PBS, pelleted by centrifugation for 5 min at 200 x g and supernatant carefully removed. The non-visible pellet was subsequently dissolved in 50 mM Na 2 CO 3 supplemented with a protease inhibitor cocktail (Roche), transferred to a 1.8 mL cryotube, snap-frozen in liquid nitrogen and stored at À80 C until further processing.
Protein extraction from patient and PDX tumors Frozen patient and PDX tumor samples were thawed on ice. Tumor samples were cut on ice and placed in separate gentleMACS M-tubes (Miltenyi, Germany) to which 9 mL homogenization buffer was added (50 mM TEAB, 1 mM DTT with protease inhibitor cocktail (Roche)). M-tubes were run on a gentleMACS instrument using pre-encoded manufacturing program Protein_01_01. The program was run three times and samples were cooled on ice between runs. After homogenization, no visible cell debris was present in the mixture. M-tubes were centrifuged at 4,000 x g at 4 C for 5 min and the supernatant was removed and run over a 70 mm nylon mesh to ensure a single cell suspension. Four times volume of ice-cold acetone (40 mL) was added to each sample followed by incubation at À20 C overnight. Samples were spun down at 7200 x g for 20 min and supernatant was discarded. The pellet was washed with ice-cold acetone, spun down and supernatant was discarded. The resulting protein pellet was redissolved in minimal volume of 8 M urea and the protein concentration was measured according to manufacturer's protocol (Bio-Rad); 100 mL of each sample were used for downstream analysis. DTT (Sigma) was added to a final concentration of 20 mM and samples were incubated for 40 minutes. Iodoacetamide (IAA) was added to a final concentration of 40 mM and samples were incubated at ambient temperature in the dark for 40 min. Samples were diluted 10 times with 900 mL 50 mM TEAB and trypsin (Promega) was added in a 1:50 (enzyme:protein) ratio incubated at 37 C overnight. Twenty mL of 100% formic acid was added and the volume reduced by vacuum centrifugation. The acidified samples were desalted using a P200 stage tip with a C18 clot and a mixture of oligo poros R2/R3 resin material. Flow through was cleaned up on an identical column and combined with the primary eluate. The combined eluate was lyophilized to completion and stored at À20 C until further processing.
Protein enrichment from mammospheres
Frozen mammosphere samples were allowed to thaw on ice. Samples were homogenized using probe sonication for 4 3 20 s at 45% amplitude with ice-cooling of samples between each sonication step. Mammosphere homogenate was washed on 10 kDa spin filters (Merck Millipore); 2 3 8M urea, 3 3 50 mM TEAB, 40 min spin/wash. Post-wash samples were dissolved in 100 mL 50 mM TEAB and DTT was added to a final concentration of 20 mM and incubated at 37 C for 20 min. IAA was added to a final concentration of 40 mM and incubated 40 min in the dark. Samples were washed twice with 50 mM TEAB on spin filters at 14,000 x g for 30 min, trypsinized overnight at 37 C on spin filters by addition of 0.5 mg trypsin in a 100 mL 50 mM TEAB reaction volume, 300 mL 50 mM TEAB was added and the spin filter was transferred to a new collection tube and centrifuged at 14,000 x g for 40 min. Peptide samples were desalted using P200 stage tips with a C18 clot and R2/R3 poros oligo material deposited on top of the clot. A small amount was taken for Bio-Rad DC protein concentration measurement and the rest of the sample was lyophilized and stored at À20 C until further use.
LC-MS/MS
Lyophilized peptide samples were dissolved in 30 mL of 25 mM Na 2 HCO 3 (Sigma Aldrich, St. Louis, MO) and analyzed in duplicate by liquid chromatography-tandem mass spectrometry (LC-MS/MS) on a nanoflow LC system (Easy-nLC 1000, ThermoFisher Scientific, San Jose, CA) coupled online with a Q-Exactive MS (ThermoFisher Scientific). Samples were resolved on a 100 mm I.D. 3 360 mm O.D. 3 20 cm long capillary column (Polymicro Technologies), which was slurry packed in-house with 5 mm, 100Å pore size C-18 silica-bonded stationary phase (Magic C18AQ). Following pre-and analytical column equilibration, each sample was loaded onto a 2-cm reversed-phase (C-18) pre-column (ThermoFisher Scientific) at 3 mL/min at 3x the injection volume with mobile phase A (0.1% formic acid in water). Peptides were eluted at a constant flow rate of 200 nL/min by development of a linear gradient of 0.33% mobile phase B (0.1% formic acid in acetonitrile) per min for 80 min and then to 95% mobile phase B for an additional 10 min. The columns were washed for 15 min at 95% mobile phase B and then quickly brought to 100% mobile phase A for the next sample injection. The MS was configured to collect broadband mass spectra (m/z 375-1800) in profile mode using the lock mass feature for the polydimethylcyclosiloxane (PCM) ion generated in the electrospray process (m/z 445.12002). Mass spectrometric conditions were set as follows: electrospray voltage, 1.7 kV; capillary temperature, 250 C; S-Lens RF level, 60%; resolution, 70,000 at m/z 200. The ion selection threshold for the broadband scan was set at 1 3 10 6 with a maximum ion accumulation time of 50 ms. The ten most abundant ions were selected for MS/MS with the following settings: ion threshold, 1 3 10 6 ; intensity threshold, 5 3 10 3 ; maximum ion accumulation time, 200 ms; resolution, 17,500 at m/z 200; isolation window, 3 amu; and dynamic exclusion, 40 s.
Quantitative protein expression analysis
All Q-Exactive raw data files were processed using Proteome Discoverer (v. 1.4.0.288; ThermoFisher Scientific) and Mascot (v. 2.2.3; Matrix Science). Mascot generic format (.mgf) files were generated in Proteome Discoverer, which were then searched against a combined UniProt human and mouse protein database (downloaded 06-10-2015, 110702 protein entries) using Mascot Daemon with the following criteria: trypsin with two missed cleavages allowed, cysteine carbamidomethylation (+57.021464) as a fixed modification and methionine oxidation (+15.994915) and lysine or N terminus carbamylation (+43.005814) as dynamic modifications. Precursor mass tolerance was set to 10 ppm and fragment mass tolerance was set to 0.5 Da. The false discovery rate (FDR) was calculated using an automatic decoy search and high confidence peptide identifications (FDR < 1%) were filtered at an ion score R 40.
Network and pathway analysis Network and pathway analysis was performed using Ingenuity Pathway Analysis (IPA, QIAGEN, https://www.qiagen.com/ingenuity) and the online GO-term enrichment analysis program Enrichnet (www.enrichnet.org). Core analysis settings in IPA were as follows: human genome, interaction network, 35 molecules/network, confidence level; experimentally observed or high confidence and direct and indirect relationships.
Online patient survival analysis
We used the established Kaplan-Meier (KM) plotter analysis platform (Szá sz et al., 2016) to analyze significant (p < 0.05) proteins from the MS data in published gene expression datasets. The online tool contains 5,143 breast cancer patients curated from 35 GEO gene expression datasets, of which 3,955 have recurrence-free survival data (RFS). Of the 3,955 breast cancer patients, 618 are defined as basal-like breast cancer patients by gene expression analysis. Basal-like breast cancer patients in the database were identified by low or no expression of ER and HER2 using Affymetrix HGU133A or HGU133plus2 arrays with cutoff values of 500 and 4800, respectively. Each percentile between the lower and upper quartiles was computed for each analyzed gene expression and the best performing threshold was used as cutoff in the Cox regression analysis; the threshold was selected to 120 months (Mihá ly et al., 2013) . Survival plots were generated with KM-plotter with hazard ratios, 95% confidence intervals and log rank P value for each selected gene probe (the best JetSet gene probe was always selected; EBP: 202735; HMGCS1: 231750; FDPS: 201275; FDFT1: 208647; NSDHL: 215093; DHCR7: 201791; LSS: 202245) . The same probes were used in the multigene classifier.
Cytotoxicity assay on MB231 cells
The MB231 cells were harvested with Tryple Express and seeded in 96-well plates at a density of 2500 cells/well. Cells were incubated for 24 h at 37 C and exposed to simvastatin (Calbiochem) at final concentrations of 0.01-10 mM, or DMSO diluent (control) in e4 Cell Reports 27, 3927-3938.e1-e6, June 25, 2019
Ethical considerations
All clinical samples were coded to maintain patient confidentiality and the study was approved by the Ethics Committee of the Region of Southern Denmark (approval no S-2008-0115) and the Danish Data Protection Agency (approval no. 2008-580035 (14/10607) ). Animal procedures were performed in accordance with a protocol approved by the Experimental Animal Committee, The Danish Ministry of Justice. The animals were housed under special pathogen-free conditions with ad libitum food and drinking water.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis of the quantitative global proteomics data were performed by the following: Proteins with low peptide spectral matches (PSMs) were filtered to include only proteins that had at least two PSMs in 50% of a given sample population. Differential expression analysis was performed using edgeR (3.0.1) package on the filtered raw PSM counts, where a general linearized model was fitted to estimate dispersion and likelihood ratio test was used to determine the proteins that were significantly altered in the comparison (p < 0.05). Moderated log-counts-per-million were calculated and used to perform clustering analysis and generate heatmaps.
The effect on MFE from MB231 and MB468 cell lines was evaluated by Poisson regression against the scrambled controls using STATA statistical software (version 15), with significance level p < 0.05. The incidence rate ratio (IRR) was expressed in % MFE. The effect of simvastatin on the MFE and single cell formation (only for cell lines) was evaluated by Poisson regression against the DMSO controls using STATA statistical software (version 15), with a minimum significance level of p < 0.05.
For qPCR experiments, median relative expression levels were normalized using the reference gene PUM1. The expression of the genes in the negative control cells were considered as 100% and the expression in the FDFT1 and CYB5R3 knockdown cell lines were measured relative to the negative control. The statistical significance (p % 0.05) of aberrant gene expression between controls and knockdowns were calculated using two-tailed unpaired Student's t test, and SEM was calculated on the dCt level and transformed using the formula 2^-(-ddCt ± SEM).
Replicate information and number of human participants and animals are indicated in the figures, figure legends and Method Details.
DATA AND CODE AVAILABILITY
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium (http://proteomecentral. proteomexchange.org/cgi/GetDataset) via the PRIDE partner repository (Vizcaíno et al., 2013) with the dataset identifier ProteomeXchange: PXD0011222.
